Get the Stockscreener App
1.38
0.73%
0.010
After Hours:
1.43
0.05
+3.62%
Galectin Therapeutics Inc stock is traded at $1.38, with a volume of 180.97K.
It is up +0.73% in the last 24 hours and down -14.29% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$1.37
Open:
$1.37
24h Volume:
180.97K
Relative Volume:
0.71
Market Cap:
$84.66M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-1.8904
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+6.98%
1M Performance:
-14.29%
6M Performance:
-48.12%
1Y Performance:
-59.17%
1-Day Range:
$1.33
$1.45
1-Week Range:
$1.25
$1.45
52-Week Range:
$0.726
$3.78
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.38 | 84.66M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress - TradingView
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World
Q2 EPS Estimate for Galectin Therapeutics Raised by Analyst - MarketBeat
FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst - The AM Reporter
HC Wainwright Analysts Raise Earnings Estimates for GALT - Defense World
HighTower Advisors LLC Buys Shares of 22,486 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Equities Analysts Set Expectations for GALT FY2029 Earnings - Defense World
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World
Galectin Therapeutics (NASDAQ:GALT) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Galectin Therapeutics Reports Promising 2024 Results - TipRanks
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times
Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World
PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World
Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St
Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance
Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks
Galectin Therapeutics shareholders elect directors, ratify auditor - MSN
Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta - Defense World
Galectin Therapeutics’ belapectin shows reduction in new varices - TipRanks
Galectin Reports 68% Reduction In New Varices With Belapectin In NAVIGATE Trial U.S. Cohort - Nasdaq
Galectin Therapeutics IncReports Significant Reduction In New Varices With Belapectin - Marketscreener.com
Belapectin shows promise in MASH cirrhosis trial - Investing.com India
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com South Africa
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - The Manila Times
Major Breakthrough: Galectin's MASH Treatment Cuts Liver Complications by 68% in Latest Trial Data - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Stratos Wealth Partners LTD. - Defense World
Largest borrow rate increases among liquid names - MSN
JPMorgan Chase & Co. Grows Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - The Malaysian Reserve
Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR
Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World
Galectin drops as trial for lead asset fails in MASH - MSN
Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World
Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Unveils Promising NAVIGATE Trial Results - TipRanks
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
40,000 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Sale |
0.88 |
13,654 |
12,044 |
26,346 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Option Exercise |
0.00 |
56,000 |
0 |
953,012 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Sale |
0.89 |
56,000 |
49,610 |
897,012 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
47,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Sale |
0.89 |
40,000 |
35,492 |
7,614 |
| Zordani Richard A. Jr. | Director |
Dec 24 '24 |
Buy |
0.82 |
10,000 |
8,164 |
42,083 |
| ELDRED KARY | Director |
Dec 24 '24 |
Buy |
0.82 |
13,469 |
11,045 |
63,682 |
| FREEMAN KEVIN D | Director |
Dec 24 '24 |
Buy |
0.81 |
10,000 |
8,134 |
44,769 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):